Program
Naproxen
Also written as “PN400”, “naproxen” and “Naproxen Sodium (Aleve, BAY117031)”.
Its studies are mostly in Pain · Osteoarthritis · Migraine Disorders · Osteoarthritis, Knee · Pain, Postoperative, led by 12 companies.
Drug pageNaproxen: every studyMany companies study it; this page follows only the 65 they lead. All 150 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayerits history only | 240 open or running | phase 4since Apr 15, 2010 | Jun 5, 2008 | none ahead |
| Pfizer | 80 open or running | phase 4since Mar 28, 2008 | Aug 17, 2006 | none ahead |
| GlaxoSmithKlineits history only | 70 open or running | phase 4since Nov 17, 2008 | Oct 14, 2005 | none ahead |
| Aralez Pharmaceuticalsits history only | 60 open or running | phase 3since Aug 18, 2006 | Aug 18, 2006 | none ahead |
| Johnson & Johnsonits history only | 50 open or running | phase 4since Dec 2, 2005 | Dec 2, 2005 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 40 open or running | phase 1since Jan 8, 2010 | Jan 8, 2010 | none ahead |
| Merckits history only | 40 open or running | phase 4since Sep 7, 2005 | Sep 7, 2005 | none ahead |
| Ache Laboratorios Farmaceuticosits history only | 20 open or running | phase 3since Jul 7, 2011 | Jul 7, 2011 | none ahead |
| Perrigoits history only | 20 open or running | phase 1since Dec 5, 2008 | Dec 5, 2008 | none ahead |
| Amgenits history only | 10 open or running | phase 2since Oct 19, 2012 | Oct 19, 2012 | none ahead |
| Analgesic Solutionsits history only | 10 open or running | no phasesince Feb 21, 2012 | Feb 21, 2012 | none ahead |
| Kenvue Brandsits history only | 11 open or running | phase 3since Oct 15, 2026 | Oct 15, 2026 | Oct 29, 2027phase 3 · NCT07948811 |
Also a collaborator on its studies: Teva Pharmaceutical Industries and Pegus Research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pfizer only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 17, 2006First study: phase 1 study in HealthyFirst studyNCT00366262 · United States
- Oct 23, 2006Phase 1 study in OsteoarthritisNCT00392080 · 340 enrolled · United States
- Mar 28, 2008Phase 4 study in Arthritis, RheumatoidNCT00650455 · 489 enrolled · United States, Canada
- Mar 28, 2008Phase 3 study in OsteoarthritisNCT00648258 · 130 enrolled · Taiwan
- Apr 1, 2008Phase 3 study in OsteoarthritisNCT00652808 · 265 enrolled · Korea, Republic of
- Aug 28, 2008Phase 1 study in Osteoarthritis ThumbsNCT00743587 · 36 enrolled · Belgium
- Jan 26, 2009Early phase 1 study in OsteoarthritisNCT00830050 · 24 enrolled · United Kingdom
- Apr 12, 2010Phase 2 study in OsteoarthritisNCT01102660 · 172 enrolled · United States
TargetBeta
“Cyclooxygenase inhibitor; Cyclooxygenase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Acetaminophenrule | Johnson & Johnson | phase 4 | 137 |
| Ibuprofenrule | Pfizer | phase 4 | 113 |
| Aspirinrule | Bayer | phase 4 | 84 |
| dexketoprofenrule | Menarini Group | phase 4 | 8 |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 7 |
| dexibuprofenrule | aponia-laboratories-inc | phase 4 | 6 |
| Benzydaminerule | Angelini Pharma | phase 4 | 4 |
| Dipyronerule | Hypera Pharma | phase 4 | 4 |
| Piroxicamrule | Taisho Pharmaceutical | phase 4 | 4 |
| Flurbiprofenrule | GlaxoSmithKline | phase 3 | 12 |
Studies
All 8 Pfizer leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01102660Osteoarthritis · United States | 2 | Completed | Feb 2011 | 172 |
| NCT00830050Osteoarthritis · United Kingdom | Early 1 | Completed | Dec 2010 | 24 |
| NCT00743587Osteoarthritis Thumbs · Belgium | 1 | Completed | Mar 2009 | 36 |
| NCT00652808Osteoarthritis · Korea, Republic of | 3 | Completed | 265 | |
| NCT00650455Arthritis, Rheumatoid · United States, Canada | 4 | Completed | Jan 2005 | 489 |
| NCT00648258Osteoarthritis · Taiwan | 3 | Completed | 130 | |
| NCT00392080Osteoarthritis · United States | 1 | Completed | 340 | |
| NCT00366262Healthy · United States | 1 | Completed |
How it is read
Names in the registry
- “Naproxen”, 17 entries
- “PN400”, 8 entries
- “naproxen”, 5 entries
- “Naproxen Sodium (Aleve, BAY117031)”, 4 entries
- “Naproxen Sodium ER (BAYH6689)”, 4 entries
Conditions, from the studies’ own filings
- Pain, 12 studies
- Osteoarthritis, 9 studies
- Migraine Disorders, 8 studies
- Osteoarthritis, Knee, 5 studies
- Pain, Postoperative, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.